Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × rrCLL × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 2561 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2074 Lymphoma, Non-Hodgkin 2049 Leukemia, Lymphocytic, Chronic, B-Cell 1766 Lymphoma, Follicular 1635 Lymphoma, Large B-Cell, Diffuse 1590 Leukemia 1167 Hodgkin Disease 1124 Lymphoma, Mantle-Cell 1105 Burkitt Lymphoma 882 Leukemia, Myeloid, Acute 877 Lymphoma, B-Cell, Marginal Zone 784 Recurrence 772 Multiple Myeloma 742 Lymphoma, B-Cell 692 Myelodysplastic Syndromes 611 Neoplasms 491 Lymphoma, T-Cell, Cutaneous 478 Waldenstrom Macroglobulinemia 466 Lymphoma, Large-Cell, Immunoblastic 456 Mycosis Fungoides 383 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 380 Lymphoma, Large-Cell, Anaplastic 362 Sezary Syndrome 321 Lymphoma, T-Cell, Peripheral 319 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 307 Hematologic Neoplasms 297 Myeloproliferative Disorders 288 Neoplasms, Plasma Cell 270 Blast Crisis 261

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡